



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :  <b>A61K 31/00</b>		A1	(11) International Publication Number: <b>WO 98/04247</b>  (43) International Publication Date: <b>5 February 1998 (05.02.98)</b>
(21) International Application Number: <b>PCT/US97/13013</b>		(74) Agent: <b>FLYNN, Kerry, A.; Biogen, Inc., 14 Cambridge Center, Cambridge, MA 02142 (US).</b>	
(22) International Filing Date: <b>24 July 1997 (24.07.97)</b>		(81) Designated States: <b>AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</b>	
(30) Priority Data: 60/022,890 25 July 1996 (25.07.96) US 60/032,786 6 December 1996 (06.12.96) US		(60) Parent Applications or Grants (63) Related by Continuation US 60/022,890 (CON) Filed on 25 July 1996 (25.07.96) US 60/032,786 (CON) Filed on 6 December 1996 (06.12.96)	
(71) Applicant (for all designated States except US): <b>BIOGEN, INC. [US/US]; 14 Cambridge Center, Cambridge, MA 02142 (US).</b>		Published <i>With international search report.</i>	
(72) Inventors; and (75) Inventors/Applicants (for US only): <b>ZHENG, Zhongli [CN/US]; 640 Marrett Road, Lexington, MA 02173 (US). ENSINGER, Carol, L. [US/US]; 76 Stonegate Road, Chelmsford, MA 01824 (US). ADAMS, Steven, P. [US/US]; 12 Berkeley Lane, Andover, MA 01810 (US).</b>		(54) Title: <b>CELL ADHESION INHIBITORS</b>	
(57) Abstract  The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.			